Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Outperform and raises the price target from $5.5 to $6.
Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Outperform and raises the price target from $5.5 to $6.